Solanty, If I had to bet and that's what we all a
Post# of 30067
Posted On: 08/05/2014 12:22:50 AM
Re: WCoastGuynCA #3062
Solanty,
If I had to bet and that's what we all are doing here. Gerald has already arranged for Lympro to be used and already has all the patients and then some he'd ever need lined up thanks to summit(s) and getting the KOL's on board. Because he took the data straight to the KOL's first, the KOL's themselves will demand Lympros use and be fighting over who gets to use it first on their patients. It's genius really, pure genius! This will actually provide 100's more test subjects and a quicker path to market plus at a lower cost to Amarantus since others will be bringing us the subjects, which I'm sure we will hear all about.
All in all, I see the CLIA not only getting done as stated but at a lower cost and Lympro to be generating income this year. I think the only thing that will slow down revenues will be having enough tests created, labs up and running, and people trained to read the results. So what if revenue is slightly lower for 2014, it just means there'll be exponentially more in 2015.
Get back on board Sol, the discount pricing days have passed. You must be tired from kicking the dead horse of more shares getting authorized around huh? What's the next dead pony you're going to kick around?
If I had to bet and that's what we all are doing here. Gerald has already arranged for Lympro to be used and already has all the patients and then some he'd ever need lined up thanks to summit(s) and getting the KOL's on board. Because he took the data straight to the KOL's first, the KOL's themselves will demand Lympros use and be fighting over who gets to use it first on their patients. It's genius really, pure genius! This will actually provide 100's more test subjects and a quicker path to market plus at a lower cost to Amarantus since others will be bringing us the subjects, which I'm sure we will hear all about.
All in all, I see the CLIA not only getting done as stated but at a lower cost and Lympro to be generating income this year. I think the only thing that will slow down revenues will be having enough tests created, labs up and running, and people trained to read the results. So what if revenue is slightly lower for 2014, it just means there'll be exponentially more in 2015.
Get back on board Sol, the discount pricing days have passed. You must be tired from kicking the dead horse of more shares getting authorized around huh? What's the next dead pony you're going to kick around?
(0)
(0)